T 细胞幼淋巴细胞白血病细胞疗法的进展
Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.
作者信息
Varadarajan Indumathy, Ballen Karen
机构信息
Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, United States.
出版信息
Front Oncol. 2022 Feb 11;12:781479. doi: 10.3389/fonc.2022.781479. eCollection 2022.
Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD.
摘要
T 细胞原淋巴细胞白血病（T-PLL）是一种罕见的侵袭性血液系统恶性肿瘤，预后较差。阿仑单抗（Campath）仍是治疗的基石，完全缓解率（CR）达 80%。造血干细胞移植（HSCT）被视为符合条件患者巩固治疗的标准疗法。然而，异基因干细胞移植也因化疗导致的感染率增加、急性移植物抗宿主病（GVHD）和慢性 GVHD 而变得复杂。本综述旨在报告关于巩固性 HSCT 疗效和并发症的现有文献。它还讨论了患者选择以及移植前后并发症（包括非典型感染和 GVHD）的重要性。
相似文献
1
Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia.T 细胞幼淋巴细胞白血病细胞疗法的进展
Front Oncol. 2022 Feb 11;12:781479. doi: 10.3389/fonc.2022.781479. eCollection 2022.
2
Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.T 细胞幼淋巴细胞白血病患者异基因造血干细胞移植后晚期复发的模式。
Acta Haematol. 2021;144(1):105-110. doi: 10.1159/000506302. Epub 2020 Apr 7.
3
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.使用CAMPATH-1H治疗T细胞幼淋巴细胞白血病的缓解率高。
Blood. 2001 Sep 15;98(6):1721-6. doi: 10.1182/blood.v98.6.1721.
4
Advances and Perspectives in the Treatment of T-PLL.T-PLL 治疗的进展和展望。
Curr Hematol Malig Rep. 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5.
5
B and T cell prolymphocytic leukaemia.B 和 T 细胞幼淋巴细胞白血病。
Best Pract Res Clin Haematol. 2019 Sep;32(3):217-228. doi: 10.1016/j.beha.2019.06.001. Epub 2019 Jun 6.
6
A patient with white blood cell counts more than a million: A diagnostic and therapeutic challenge.一名白细胞计数超过一百万的患者：诊断与治疗挑战
Bisturi (S Juan). 2016 Mar-Jun;2016:12-16.
7
Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia.难治性 T 幼淋巴细胞白血病采用维奈托克和芦可替尼联合治疗的部分缓解。
Hematology. 2023 Dec;28(1):2237342. doi: 10.1080/16078454.2023.2237342.
8
Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).T 细胞幼淋巴细胞白血病的异基因造血干细胞移植：来自法国干细胞移植协会（SFGM-TC）的报告
Eur J Haematol. 2015 Mar;94(3):265-9. doi: 10.1111/ejh.12430. Epub 2014 Sep 13.
9
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关：日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
10
Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.一名患有伴有小肠受累的T-原淋巴细胞白血病患者接受异基因骨髓移植。
Int J Clin Oncol. 2003 Dec;8(6):391-4. doi: 10.1007/s10147-003-0349-1.
引用本文的文献
1
Single-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia.单细胞测序揭示了T-原淋巴细胞白血病中非恶性B细胞和肿瘤细胞中共享的克隆特征。
Blood Neoplasia. 2025 Feb 16;2(2):100076. doi: 10.1016/j.bneo.2025.100076. eCollection 2025 May.
2
T-cell prolymphocytic leukemia, a case report and review of the literature.T细胞幼淋巴细胞白血病：一例报告并文献复习
Oncol Res. 2025 Feb 28;33(3):505-517. doi: 10.32604/or.2025.058175. eCollection 2025.
3
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.T 细胞前淋巴细胞白血病：诊断、发病机制与治疗。
Int J Mol Sci. 2023 Jul 28;24(15):12106. doi: 10.3390/ijms241512106.
4
Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion.T 细胞前淋巴细胞白血病复发性罕见表现为弥漫性全身性皮肤病变。
J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231176223. doi: 10.1177/23247096231176223.
本文引用的文献
1
Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.贝罗莫苏德利治疗 2 线及以上治疗后的慢性移植物抗宿主病：ROCKstar 研究。
Blood. 2021 Dec 2;138(22):2278-2289. doi: 10.1182/blood.2021012021.
2
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性急性移植物抗宿主病。
N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.
3
Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.T 细胞幼淋巴细胞白血病患者异基因造血干细胞移植后晚期复发的模式。
Acta Haematol. 2021;144(1):105-110. doi: 10.1159/000506302. Epub 2020 Apr 7.
4
Advances and Perspectives in the Treatment of T-PLL.T-PLL 治疗的进展和展望。
Curr Hematol Malig Rep. 2020 Apr;15(2):113-124. doi: 10.1007/s11899-020-00566-5.
5
Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia.鞘内注射阿仑单抗：治疗难治性脑膜 T 细胞幼淋巴细胞白血病的一种潜在方法。
Blood Adv. 2019 Nov 12;3(21):3333-3336. doi: 10.1182/bloodadvances.2019000289.
6
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.伊布替尼治疗前期治疗失败后的慢性移植物抗宿主病：1 期 b/2 研究的 1 年更新。
Biol Blood Marrow Transplant. 2019 Oct;25(10):2002-2007. doi: 10.1016/j.bbmt.2019.06.023. Epub 2019 Jun 28.
7
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.托法替布（泛JAK抑制剂）与鲁索替尼（JAK1/2抑制剂）联合用于治疗伴有JAK3突变的难治性T细胞幼淋巴细胞白血病（T-PLL）。
Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18.
8
Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies.嵌合抗原受体T细胞（CAR-T细胞）靶向独特的互补决定区3（CDR3）表位是治疗T细胞恶性肿瘤的一种可行方法。
Leukemia. 2019 Sep;33(9):2315-2319. doi: 10.1038/s41375-019-0455-3. Epub 2019 Apr 8.
9
Chimeric Antigen Receptors for T-Cell Malignancies.用于治疗T细胞恶性肿瘤的嵌合抗原受体
Front Oncol. 2019 Mar 5;9:126. doi: 10.3389/fonc.2019.00126. eCollection 2019.
10
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).EBMT 前瞻性观察性研究：异基因造血干细胞移植治疗 T 幼淋巴细胞白血病（T-PLL）。
Bone Marrow Transplant. 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21.
Zotero 插件